PACTR202003507062297Other4 期
Evaluation of open-label Pre exposure prophylaxis (PrEP) delivery amongKenyan women
niversity of Washington0 个研究点目标入组 1,000 人开始时间: 2020年3月12日最近更新:
试验速览
- 阶段
- 4 期
- 状态
- Other
- 发起方
- 入组人数
- 1,000
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 19 Year(s) 至 44 Year(s)（—）
- 性别
- Female
入选标准
- •For HIV uninfected women
- •-Age 16-25
- •o16 and 17 year olds, where permissible by national regulations and local IRB approval
- •-Able and willing to provide written informed consent
- •-Recently sexually active (defined as having had vaginal intercourse at least once in the previous three months)
- •-HIV uninfected based on negative HIV rapid tests, on the date of enrollment
排除标准
- •Not within the required age range
- •Not willing to provide informed consent
- •Not sexually active
- •HIV infected
研究者
相似试验
进行中（未招募）
不适用
An Open-Label Study to Evaluate Prophylaxis Treatment, and to Characterize the Efficacy, Safety and Pharmacokinetics of B-Domain Deleted Recombinant Factor VIII Albumin Free (Moroctocog alfa [AF-CC]) in Children With Hemophilia A - N/AYounger Male Haemophilia A patients < 6 years of age with moderately severe to severe hemophilia A (FVIII:C = 2%), with previous FVIII replacement therapy experience (= 50 exposure days to any FVIII replacement product).EUCTR2006-005575-17-DEWyeth Pharmaceuticals Inc. acting through its division Wyeth Research, a Pfizer Company72
进行中（未招募）
1 期
An Open-Label Study to Evaluate Prophylaxis Treatment, and to Characterize the , Efficacy, Safety and Pharmacokinetics of B Domain Deleted Recombinant Factor VIII Albumin Free (ReFacto AF) in Children With Hemophilia A Estudio abierto para evaluar el tratamiento profiláctico y para caracterizar la eficacia, la seguridad y la farmacocinética del factor VIII recombinante con delección del dominio B sin albúmina (ReFacto® AF) en niños con hemofilia A - N/AEUCTR2006-005575-17-ESWyeth Research Division of Wyeth Pharmaceuticals Inc.65
进行中（未招募）
不适用
An Open-Label Study to Evaluate Prophylaxis Treatment, and to Characterize the Efficacy, Safety, and Pharmacokinetics of B Domain Deleted Recombinant Factor VIII Albumin Free (Moroctocog alfa [AF-CC]) in Children With Hemophilia A - NDHemophilia AMedDRA version: 12.0Level: LLTClassification code 10056493Term: Haemophilia A without inhibitorsEUCTR2006-005575-17-ITWyeth Research Division of Wyeth Pharmaceuticals Inc.72
进行中（未招募）
1 期
A study to compare the difference in effect between treating bleeds after they occur or giving preventative treatment on an ongoing basis, also to determine levels of Factor VIII in the blood following treatment in children with Hemophilia AEUCTR2006-005575-17-ATWyeth Pharmaceuticals Inc. acting through its division Wyeth Research, a Pfizer Company72
已完成
不适用
An open-label, non-controlled trial of prophylactic administration of voriconazole in patients who undergo allogeneic hematopoietic stem cell transplantation.Invasive fungal infectionJPRN-UMIN000027218ational Hospital Organization Nagoya Medical Center30